Supplemental Material: supporting references
Supporting references for immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures in ASD
Immune dysregulation and inflammation
A total of 437 publications investigated a relationship between immune dysregulation and/or inflammation and ASD, with 416implicating a relationship between immune dysregulation and/or inflammationand ASD. Twenty-one publications (all clinical studies) 1-21failed to find an association between immune dysregulation or inflammation and ASD. Publications implicating a relationship between immune dysregulation and/or inflammation and ASD either reported about generalized immune dysregulation/inflammation, or reported these in a specific organ system (e.g., brain or gastrointestinal tract). An association between ASD and generalized immune dysregulation and/or inflammation was implicated in 320publications, including 155 clinical studies 22-176, 91 review articles or hypothesis-generating papers177-267, 34 studies using animal models 268-301, 19 publications on Rett syndrome 302-320 and 21 clinical-treatment studies321-341. Neuroinflammation or brain immune dysregulation were implicated in ASD in 52 clinical studies 342-393 and 13 review articles 394-406. Gastrointestinal (GI) inflammation or immune dysregulation were implicated in ASD in 24 clinical studies407-430 and 7 review articles 431-437. Ninety-five publications 438-532(not included in the initial 437 publications) discussed a possible link between vaccines (mainly MMR vaccine) and immune dysregulation and/or inflammation (especially of the GI tract) in ASD and were not included in this analysis; the majority of these 95 publications reported no significant association.
Oxidative stress
A total of 115 publications investigated a relationship between oxidative stress and ASD, with all 115 implicating an association. These publicationsincluded51 clinical studies 22, 27, 32, 40, 88, 119, 120, 150, 173, 337, 345, 346, 354, 533-570, 41 review articles or hypothesis-generating papers 184, 188, 190, 194, 200, 203, 204, 206-208, 215, 221, 239, 253-255, 402, 405, 571-593, 7 clinical-treatment studies 322, 594-599, 6 publications reporting animal models 283, 600-604 and 10 publications on Rett syndrome 605-614.
Mitochondrial dysfunction
A total of 153 publications investigated a relationship between mitochondrial dysfunction and ASD or Rett syndrome, with 145 implicating a relationshipand 8publications (all clinical studies)failing to find an association between mitochondrial dysfunction and ASD 615-621 or Rett syndrome 622. The 145 publications implicating an association between mitochondrial dysfunction and ASD included 63 clinical studies 32, 108, 172, 536, 539, 541, 552, 558, 569, 570, 623-675, 22 review articles or hypothesis-generating papers 200, 203, 204, 207, 208, 215, 253, 254, 402, 573, 578, 591, 676-685,11 publications reporting animal models 283, 296, 297, 602, 686-692 and 49 studies of Rett syndrome306, 607-610, 613, 693-735.
Environmental toxicant exposures
A total of 190 publicationsinvestigated a relationship between environmental toxicant exposures (such as pesticides, chemicals, phthalates, PCBs, solvents, heavy metals or other pollutants) and ASD, with 170 implicating a relationship and 20 publications(19 clinical studies and 1 letter to the editor) 3, 15, 151, 736-752failing to find an association between environmental toxicant exposures and ASD. The 170 publications implicating an association between environmental toxicant exposures and ASD included 71 clinical studies35, 66, 157, 159, 322, 379, 386, 387, 412, 516, 533, 537, 541, 545, 546, 552, 561, 567, 594, 623, 753-803, 67 review articles or hypothesis-generating papers 180, 182, 186-188, 192, 194, 203-205, 207, 215, 222, 225, 233, 234, 250, 402, 437, 573, 575, 578, 579, 583, 585, 587, 804-844, 26 publications of animal models 270, 277, 278, 283, 293, 296, 600, 602, 845-862and 6 clinical studies on treatments for toxicants863-868. Forty-seven publications (not included in the initial 190 publications) examined a possible association between thimerosal (ethylmercury) in vaccines and ASD, with 37 publications reporting no significant association21, 447, 449, 459, 462, 481, 497, 498, 869-897 and 10(all but one publication were from the same authors) reporting some type of an association457, 898-906. No publications reported an association or lack of an association between environmental toxicant exposures and Rett syndrome.
References
1.Hornig M, Briese T, Buie T, Bauman ML, Lauwers G, Siemetzki U et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS ONE 2008; 3(9): e3140.
2.Croen LA, Goines P, Braunschweig D, Yolken R, Yoshida CK, Grether JK et al. Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) Study. Autism Res 2008; 1(2): 130-137.
3.Rosen NJ, Yoshida CK, Croen LA. Infection in the first 2 years of life and autism spectrum disorders. Pediatrics 2007; 119(1): e61-69.
4.Sweeten TL, Taylor MW, Posey DJ, McDougle CJ. Plasma kynurenine levels in autistic disorder. Journal of Developmental and Physical Disabilities 2006; 18(4): 419-426.
5.Robertson MA, Sigalet DL, Holst JJ, Meddings JB, Wood J, Sharkey KA. Intestinal permeability and glucagon-like peptide-2 in children with autism: a controlled pilot study. J Autism Dev Disord 2008; 38(6): 1066-1071.
6.Goines P, Schauer J, Heuer L, Ashwood P, Van de Water J. Beta-2-microglobulin in autism spectrum disorders. American Journal of Biochemistry and Biotechnology 2007; 3(2): 87-91.
7.Abolfazli R, Mirbagheri SA, Zabihi AA, Abouzari M. Autism and celiac disease: Failure to validate the hypothesis of a possible link. Iranian Red Crescent Medical Journal 2009; 11(4): 442-444.
8.Cook EH, Jr., Perry BD, Dawson G, Wainwright MS, Leventhal BL. Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives, and control subjects. J Autism Dev Disord 1993; 23(1): 67-78.
9.Handen BL, Melmed RD, Hansen RL, Aman MG, Burnham DL, Bruss JB et al. A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord 2009; 39(5): 796-805.
10.Satterfield BC, Garcia RA, Gurrieri F, Schwartz CE. PCR and serology find no association between xenotropic murine leukemia virus-related virus (XMRV) and autism. Mol Autism 2010; 1(1): 14.
11.Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 2002; 325(7361): 419-421.
12.Fernell E, Fagerberg UL, Hellstrom PM. No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatr 2007; 96(7): 1076-1079.
13.Croen LA, Matevia M, Yoshida CK, Grether JK. Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and risk of autism spectrum disorders. Am J Obstet Gynecol 2008; 199(3): 234 e231-236.
14.DeFelice ML, Ruchelli ED, Markowitz JE, Strogatz M, Reddy KP, Kadivar K et al. Intestinal cytokines in children with pervasive developmental disorders. Am J Gastroenterol 2003; 98(8): 1777-1782.
15.Singh VK, Hanson J. Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal. Pediatr Allergy Immunol 2006; 17(4): 291-296.
16.Kirkman NJ, Libbey JE, Sweeten TL, Coon HH, Miller JN, Stevenson EK et al. How relevant are GFAP autoantibodies in autism and Tourette Syndrome? J Autism Dev Disord 2008; 38(2): 333-341.
17.Libbey JE, Coon HH, Kirkman NJ, Sweeten TL, Miller JN, Stevenson EK et al. Are there enhanced MBP autoantibodies in autism? J Autism Dev Disord 2008; 38(2): 324-332.
18.Morris CM, Zimmerman AW, Singer HS. Childhood serum anti-fetal brain antibodies do not predict autism. Pediatr Neurol 2009; 41(4): 288-290.
19.Anlar B, Oktem F, Torok T. Human parvovirus B19 antibodies in infantile autism. J Child Neurol 1994; 9(1): 104-105.
20.Atladottir HO, Thorsen P, Schendel DE, Ostergaard L, Lemcke S, Parner ET. Association of hospitalization for infection in childhood with diagnosis of autism spectrum disorders: a Danish cohort study. Arch Pediatr Adolesc Med 2010; 164(5): 470-477.
21.Singh VK, Rivas WH. Detection of antinuclear and antilaminin antibodies in autistic children who received thimerosal-containing vaccines. J Biomed Sci 2004; 11(5): 607-610.
22.Yao Y, Walsh WJ, McGinnis WR, Pratico D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 2006; 63(8): 1161-1164.
23.Williams G, McChane RH, Schikler K. Case Report: 6-Year-Old Male with Autism and Systemic Onset Juvenile Rheumatoid Arthritis. Journal of Developmental and Physical Disabilities 2004; 16(1): 117-123.
24.Wiest MM, German JB, Harvey DJ, Watkins SM, Hertz-Picciotto I. Plasma fatty acid profiles in autism: a case-control study. Prostaglandins Leukot Essent Fatty Acids 2009; 80(4): 221-227.
25.Tani P, Lindberg N, Matto V, Appelberg B, Nieminen-von Wendt T, von Wendt L et al. Higher plasma ACTH levels in adults with Asperger syndrome. J Psychosom Res 2005; 58(6): 533-536.
26.Suzuki K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ et al. Decreased serum levels of epidermal growth factor in adult subjects with high-functioning autism. Biol Psychiatry 2007; 62(3): 267-269.
27.Suh JH, Walsh WJ, McGinnis WR, Lewis A, Ames BN. Altered sulfur amino acid metabolism in immune cells of children diagnosed with autism American Journal of Biochemistry and Biotechnology 2008; 4(2): 105-113.
28.Sugihara G, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ et al. Decreased serum levels of hepatocyte growth factor in male adults with high-functioning autism. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(2): 412-415.
29.Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 2006; 21(6): 444-449.
30.Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(8): 1472-1477.
31.Russo AJ. Anti-metallothionein IgG and levels of metallothionein in autistic children with GI disease. Drug, Healthcare and Patient Safety 2009; 1(1): 1-8.
32.Pastural E, Ritchie S, Lu Y, Jin W, Kavianpour A, Khine Su-Myat K et al. Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids 2009; 81(4): 253-264.
33.Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 187-190.
34.Odell D, Maciulis A, Cutler A, Warren L, McMahon WM, Coon H et al. Confirmation of the association of the C4B null allelle in autism. Hum Immunol 2005; 66(2): 140-145.
35.Nicolson GL, Gan R, Nicolson NL, Haier J. Evidence for Mycoplasma ssp., Chlamydia pneunomiae, and human herpes virus-6 coinfections in the blood of patients with autistic spectrum disorders. J Neurosci Res 2007; 85(5): 1143-1148.
36.Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001; 49(5): 597-606.
37.Mostafa GA, Hamza RT, El-Shahawi HH. Allergic manifestations in autistic children: Relation to disease severity. Journal of Pediatric Neurology 2008; 6(2): 115-123.
38.Mostafa GA, El-Sherif DF, Hamza RT, Al Shehab A. Hyperserotonemia in Egyptian autistic children: Relation to allergic manifestations. Journal of Pediatric Neurology 2008; 6(3): 227-236.
39.Momeni N, Nordstrom BM, Horstmann V, Avarseji H, Sivberg BV. Alterations of prolyl endopeptidase activity in the plasma of children with autistic spectrum disorders. BMC Psychiatry 2005; 5: 27.
40.Karamouzi A, Kovachev D, Karamouzis I, Antoniadou-Hitoglou M, Tsikoulas I, Aggelopoulou-Sakadami N. Saliva levels of 15-F2t-Isoprostane as biomarker of lipid peroxidation in autistic children. European Journal of Inflammation 2007; 5(3): 141-144.
41.Kajizuka M, Miyachi T, Matsuzaki H, Iwata K, Shinmura C, Suzuki K et al. Serum levels of platelet-derived growth factor BB homodimers are increased in male children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2009.
42.Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y et al. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(8): 1529-1531.
43.Cazzullo AG, Musetti MC, Musetti L, Bajo S, Sacerdote P, Panerai A. Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur Neuropsychopharmacol 1999; 9(4): 361-366.
44.Bell JG, Miller D, MacDonald DJ, MacKinlay EE, Dick JR, Cheseldine S et al. The fatty acid compositions of erythrocyte and plasma polar lipids in children with autism, developmental delay or typically developing controls and the effect of fish oil intake. Br J Nutr 2010; 103(8): 1160-1167.
45.Fujita-Shimizu A, Suzuki K, Nakamura K, Miyachi T, Matsuzaki H, Kajizuka M et al. Decreased serum levels of adiponectin in subjects with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(3): 455-458.
46.Fatemi SH, Stary JM, Egan EA. Reduced blood levels of reelin as a vulnerability factor in pathophysiology of autistic disorder. Cell Mol Neurobiol 2002; 22(2): 139-152.
47.Enstrom A, Onore C, Tarver A, Hertz-Picciotto I, Hansen R, Croen L et al. Peripheral blood leukocyte production of BDNF following mitogen stimulation in early onset and regressive autism. American Journal of Biochemistry and Biotechnology 2008; 4(2): 121-129.
48.Enstrom A, Onore C, Hertz-Picciotto I, Hansen R, Croen L, Van de Water J et al. Detection of IL-17 and IL-23 in plasma samples of children with autism. Am J Biochem Biotech 2008; 4(2): 114-120.
49.Engstrom HA, Ohlson S, Stubbs EG, Maciulis A, Caldwell V, Odell JD et al. Decreased Expression of CD95 (FAS/APO-1) on CD4+ T-lymphocytes from Participants with Autism. Journal of Developmental and Physical Disabilities 2003; 15(2): 155-163.
50.Curran LK, Newschaffer CJ, Lee LC, Crawford SO, Johnston MV, Zimmerman AW. Behaviors associated with fever in children with autism spectrum disorders. Pediatrics 2007; 120(6): e1386-1392.
51.Corbett BA, Kantor AB, Schulman H, Walker WL, Lit L, Ashwood P et al. A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry 2007; 12(3): 292-306.
52.Bu B, Ashwood P, Harvey D, King IB, Water JV, Jin LW. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot Essent Fatty Acids 2006; 74(4): 215-221.
53.Brambilla F, Guareschi-Cazzullo A, Tacchini C, Musetti C, Panerai AE, Sacerdote P. Beta-endorphin and cholecystokinin 8 concentrations in peripheral blood mononuclear cells of autistic children. Neuropsychobiology 1997; 35(1): 1-4.
54.Boris M, Goldblatt A. Pollen exposure as a cause for the deterioration of neurobehavioral function in children with autism and attention deficit hyperactive disorder: Nasal pollen challenge. J Nutritional Environmental Medicine 2004; 14(1): 47-54.
55.Atladottir HO, Thorsen P, Ostergaard L, Schendel DE, Lemcke S, Abdallah M et al. Maternal Infection Requiring Hospitalization During Pregnancy and Autism Spectrum Disorders. J Autism Dev Disord 2010.
56.Anlar B, Oktem F, Bakkaloglu B, Haliloglu M, Oguz H, Unal F et al. Urinary epidermal and insulin-like growth factor excretion in autistic children. Neuropediatrics 2007; 38(3): 151-153.
57.Al-Ayadhi LY. Pro-inflammatory cytokines in autistic children in central Saudi Arabia. Neurosciences 2005; 10(2): 155-158.
58.Al-Ayadhi LY. Autoimmune connection of autism in Central Saudi Arabia. Neurosciences 2005; 10(4): 265-267.
59.Angelidou A, Francis K, Vasiadi M, Alysandratos KD, Zhang B, Theoharides A et al. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation 2010; 7(1): 48.
60.Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen RL, Croen LA et al. Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008.
61.Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2010.
62.Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Altered T cell responses in children with autism. Brain Behav Immun 2010.
63.Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol 2010.
64.Ashwood P, Kwong C, Hansen R, Hertz-Picciotto I, Croen L, Krakowiak P et al. Brief report: Plasma leptin levels are elevated in autism: Association with early onset phenotype? J Autism Dev Disord 2008; 38(1): 169-175.
65.Ashwood P, Nguyen DV, Hessl D, Hagerman RJ, Tassone F. Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis? Brain Behav Immun 2010; 24(6): 898-902.
66.Ashwood P, Schauer J, Pessah IN, de Water JV. Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with autism spectrum disorders. J Neuroimmunol 2009; 208(1-2): 130-135.
67.Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009; 124(2): 687-694.
68.Bakkaloglu B, Anlar B, Anlar FY, Oktem F, Pehlivanturk B, Unal F et al. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008.
69.Bidet B, Leboyer M, Descours B, Bouvard MP, Benveniste J. Allergic sensitization in infantile autism. J Autism Dev Disord 1993; 23(2): 419-420.
70.Blardi P, de Lalla A, Ceccatelli L, Vanessa G, Auteri A, Hayek J. Variations of plasma leptin and adiponectin levels in autistic patients. Neurosci Lett 2010; 479(1): 54-57.
71.Campbell DB, D'Oronzio R, Garbett K, Ebert PJ, Mirnics K, Levitt P et al. Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann Neurol 2007; 62(3): 243-250.
72.Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A 2006; 103(45): 16834-16839.
73.Chen CP, Lin SP, Chern SR, Tsai FJ, Wu PC, Lee CC et al. A de novo 7.9 Mb deletion in 22q13.2-->qter in a boy with autistic features, epilepsy, developmental delay, atopic dermatitis and abnormal immunological findings. Eur J Med Genet 2010; 53(5): 329-332.
74.Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999; 14(6): 388-394.
75.Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005; 159(2): 151-157.
76.Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 2002; 45(1): 1-6.
77.Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E et al. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 2002; 32(8): 1457-1463.
78.Daniels WW, Warren RP, Odell JD, Maciulis A, Burger RA, Warren WL et al. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology 1995; 32(3): 120-123.
79.Denney DR, Frei BW, Gaffney GR. Lymphocyte subsets and interleukin-2 receptors in autistic children. J Autism Dev Disord 1996; 26(1): 87-97.
80.Emanuele E, Orsi P, Boso M, Broglia D, Brondino N, Barale F et al. Low-grade endotoxemia in patients with severe autism. Neurosci Lett 2010; 471(3): 162-165.
81.Emanuele E, Boso M, Brondino N, Pietra S, Barale F, Ucelli di Nemi S et al. Increased serum levels of high mobility group box 1 protein in patients with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(4): 681-683.
82.Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 2008.
83.Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun 2010; 24(1): 64-71.
84.Enstrom A, Krakowiak P, Onore C, Pessah IN, Hertz-Picciotto I, Hansen RL et al. Increased IgG4 levels in children with autism disorder. Brain Behav Immun 2009; 23(3): 389-395.
85.Evers M, Cunningham-Rundles C, Hollander E. Heat shock protein 90 antibodies in autism. Mol Psychiatry 2002; 7 Suppl 2: S26-28.
86.Ferrante P, Saresella M, Guerini FR, Marzorati M, Musetti MC, Cazzullo AG. Significant association of HLA A2-DR11 with CD4 naive decrease in autistic children. Biomed Pharmacother 2003; 57(8): 372-374.
87.Ferrari P, Marescot MR, Moulias R, Bursztejn C, Deville Chabrolle A, Thiollet M et al. [Immune status in infantile autism. Correlation between the immune status, autistic symptoms and levels of serotonin]. Encephale 1988; 14(5): 339-344.
88.Frye RE. Central tetrahydrobiopterin concentration in neurodevelopmental disorders. Front Neurosci 2010; 4: 52.
89.Geier DA, Geier MR. A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders. J Matern Fetal Neonatal Med 2007; 20(5): 385-390.
90.Geier DA, Mumper E, Gladfelter B, Coleman L, Geier MR. Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment. Neuro Endocrinol Lett 2008; 29(2): 272-280.
91.Giuliodori K, Ganzetti G, Campanati A, Simonetti O, Marconi B, Offidani A. A non-responsive chronic autoimmune urticaria in a 12-year-old autistic girl treated with cyclosporin. J Eur Acad Dermatol Venereol 2009; 23(5): 619-620.
92.Grether JK, Croen LA, Anderson MC, Nelson KB, Yolken RH. Neonatally measured immunoglobulins and risk of autism. Autism Res 2010.
93.Grigorenko EL, Han SS, Yrigollen CM, Leng L, Mizue Y, Anderson GM et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 2008; 122(2): e438-445.
94.Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998; 85(1): 106-109.
95.Harrison KL, Pheasant AE. Analysis of urinary pterins in autism. Biochem Soc Trans 1995; 23(4): 603S.
96.Heuer L, Ashwood P, Schauer J, Goines P, Krakowiak P, Hertz-Picciotto I et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res 2008; 1(5): 275-283.
97.Hollander E, DelGiudice-Asch G, Simon L, Schmeidler J, Cartwright C, DeCaria CM et al. B lymphocyte antigen D8/17 and repetitive behaviors in autism. Am J Psychiatry 1999; 156(2): 317-320.
98.Hu VW, Nguyen A, Kim KS, Steinberg ME, Sarachana T, Scully MA et al. Gene expression profiling of lymphoblasts from autistic and nonaffected sib pairs: altered pathways in neuronal development and steroid biosynthesis. PLoS One 2009; 4(6): e5775.
99.Hunter LC, O'Hare A, Herron WJ, Fisher LA, Jones GE. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol 2003; 45(2): 121-128.
100.Iseri E, Guney E, Ceylan MF, Yucel A, Aral A, Bodur S et al. Increased Serum Levels of Epidermal Growth Factor in Children with Autism. J Autism Dev Disord 2010.
101.Iwata Y, Tsuchiya KJ, Mikawa S, Nakamura K, Takai Y, Suda S et al. Serum levels of P-selectin in men with high-functioning autism. Br J Psychiatry 2008; 193(4): 338-339.
102.Jyonouchi H. Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic. Expert Rev Clin Immunol 2010; 6(3): 397-411.
103.Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflammation 2008; 5: 52.